Opko Health Inc
Opko Health Inc (OPK) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Miami, United States and has 2,275 employees. The company is worth $1.22B. Revenue was $606.88M in fiscal 2025, down 14.9% from the year before. It reported a net loss of $225.68M. The share price is 7.9% below its 52-week high of $1.77. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $2.13M. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -61.1% over 5Y.
today you would have $403.69▼ -59.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.26 | $1.47 | $1.51 | $1.25 | $4.81 | $3.95 | $1.47 | $3.01 | $4.90 | $9.30 | $10.05 | $9.99 | $8.44 | $4.81 | $4.90 | $3.67 | $1.83 | |
| P/E | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| KARDKardigan, Inc. | $13.03 | — | 2.0x | 0.00% | — | $1.22B |
| SNDXSyndax Pharmaceuticals Inc | $13.57 | — | 80.3x | 0.00% | -255.93% | $1.21B |
| INNVInnovAge Holding Corp. | $8.85 | — | 5.1x | 0.00% | -0.26% | $1.21B |
| TRAXFirst Tracks Biotherapeutics, Inc. | $34.46 |
| — |
| — |
| — |
| — |
| — |
| 79.0x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 2.6x | 1.6x | 1.4x | 1.2x | 1.0x | 1.8x | 1.8x | 1.1x | 1.9x | 2.6x | 4.2x | 11.2x | 49.5x | 36.1x | 33.2x | 51.7x | 32.9x | 96.6x |
| P/B | 1.9x | 0.8x | 0.7x | 0.8x | 0.6x | 1.9x | 1.6x | 0.6x | 1.0x | 1.5x | 2.5x | 2.7x | 5.4x | 4.0x | 8.7x | 9.0x | 40.7x | 13.5x |
| EPS | -$0.30 | -$0.08 | -$0.25 | -$0.46 | -$0.05 | $0.05 | -$0.53 | -$0.27 | -$0.55 | -$0.10 | -$0.06 | -$0.41 | -$0.32 | -$0.11 | -$0.01 | -$0.08 | -$0.15 |
| Profit margin | -28.59% | -37.19% | -7.46% | -21.87% | -32.70% | -1.70% | 2.13% | -34.92% | -15.45% | -28.59% | -3.96% | -6.11% | -188.39% | -118.52% | -61.75% | -4.59% | -66.42% | -681.60% |
| ROE | -13.59% | -17.80% | -3.90% | -13.59% | -21.03% | -1.79% | 1.83% | -19.50% | -8.54% | -16.56% | -2.36% | -1.50% | -20.38% | -13.05% | -16.19% | -0.80% | -82.10% | -95.30% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 7.2x |
| 0.00% |
| — |
| $1.23B |
| GDRXGoodRx Holdings, Inc. | $3.62 | 72.4x | 1.9x | 0.00% | 2.52% | $1.23B |
| TNDMTandem Diabetes Care Inc | $17.15 | — | 9.1x | 0.00% | -48.03% | $1.19B |